ImmunoCellular Therapeutics Price To Earning vs. Cash And Equivalents

IMUCDelisted Stock  USD 0.47  0.00  0.00%   
Based on ImmunoCellular Therapeutics' profitability indicators, ImmunoCellular Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess ImmunoCellular Therapeutics' ability to earn profits and add value for shareholders.
For ImmunoCellular Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmunoCellular Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmunoCellular Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmunoCellular Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmunoCellular Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Please note, there is a significant difference between ImmunoCellular Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunoCellular Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunoCellular Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ImmunoCellular Therapeutics Cash And Equivalents vs. Price To Earning Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ImmunoCellular Therapeutics's current stock value. Our valuation model uses many indicators to compare ImmunoCellular Therapeutics value to that of its competitors to determine the firm's financial worth.
ImmunoCellular Therapeutics is rated below average in price to earning category among its peers. It is rated fifth overall in cash and equivalents category among its peers creating about  46,657,500  of Cash And Equivalents per Price To Earning. Comparative valuation analysis is a catch-all model that can be used if you cannot value ImmunoCellular Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ImmunoCellular Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

ImmunoCellular Cash And Equivalents vs. Price To Earning

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

ImmunoCellular Therapeutics

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
0.02 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

ImmunoCellular Therapeutics

Cash

 = 

Bank Deposits

+

Liquidities

 = 
933.15 K
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

ImmunoCellular Cash And Equivalents Comparison

ImmunoCellular Therapeutics is currently under evaluation in cash and equivalents category among its peers.

ImmunoCellular Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ImmunoCellular Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmunoCellular Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of ImmunoCellular Therapeutics' change in net profit over the period of time. It can combine multiple indicators of ImmunoCellular Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.

ImmunoCellular Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ImmunoCellular Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmunoCellular Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmunoCellular Therapeutics' important profitability drivers and their relationship over time.

Use ImmunoCellular Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoCellular Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoCellular Therapeutics will appreciate offsetting losses from the drop in the long position's value.

ImmunoCellular Therapeutics Pair Trading

ImmunoCellular Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to ImmunoCellular Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmunoCellular Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmunoCellular Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmunoCellular Therapeutics to buy it.
The correlation of ImmunoCellular Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmunoCellular Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmunoCellular Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmunoCellular Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ImmunoCellular Therapeutics position

In addition to having ImmunoCellular Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Blockchain Thematic Idea Now

Blockchain
Blockchain Theme
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in ImmunoCellular Pink Sheet

If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities